-
Quintiles To Quantify Healthcare Decisions
4/2/2012
Quintiles and Archimedes Inc. recently announced an agreement to co-promote clinical and commercial solutions for biopharmaceutical companies to help reduce the time and expense associated with developing and marketing novel therapies.
-
Tarsa Therapeutics Signs Commercial Supply Agreement For Its Ostora Oral Calcitonin Product With QS Pharma
4/2/2012
Tarsa Therapeutics recently announced it has entered into a commercial supply agreement with QS Pharma for the bulk manufacture of its OSTORA oral recombinant salmon calcitonin tablet.
-
ScinoPharm And National Health Research Institutes (NHRI) Announce Jointly Developed Diabetes Drug Approved For Phase I Clinical Trial
3/26/2012
ScinoPharm (TWSE1789), a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, today announced its CRO project, DBPR108, commissioned by the National Health Research Institutes (NHRI), has received approval by Taiwan and the U.S. Food and Drug Administration (FDA) to commence a Phase I clinical trial.
-
Recipharm Contracted By ViroPharma To Complete Full Commercial Manufacture Of DuoCort's Plenadren
3/19/2012
Recipharm and ViroPharma today signed a commercial contract to initiate supply of Plenadren for named patient use.
-
EMD Millipore Partners With Charles River Laboratories For Improved Viral Clearance Studies
2/28/2012
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, recently announced it will be partnering with Charles River Laboratories International, Inc. of Wilmington, MA, to exclusively license EMD Millipore’s TrueSpike technology.
-
Pliaglis Regulatory Update FDA Sets PDUFA Date Of April 16, 2012
2/22/2012
Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, recently announced an update to Pliaglis regulatory approval in the U.S. and the E.U.
-
Evotec And IR Pharma Establish Drug Discovery Alliance In The Field Of Respiratory
2/22/2012
Evotec AG and IR Pharma recently announced that they have entered into an exclusive strategic alliance to provide integrated drug discovery solutions to Pharmaceutical and Biotech companies in the field of Respiratory Diseases.
-
Catalent Completes Acquisition Of Clinical Trials Supplies Business Of Aptuit LLC
2/22/2012
Catalent Pharma Solutions recently announced that it has completed the acquisition of the Clinical Trial Supplies business of Aptuit LLC.
-
PCI Sponsors MassBio's Massachusetts CRO/CMO Symposium
2/22/2012
PCI (www.pcisynthesis.com), a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products, today announced its major sponsorship of the inaugural one-day Massachusetts Biotechnology Council (MassBio) CRO/CMO Symposium.
-
Lonza Confirms Talks With South African Government Regarding The Establishment Of A Joint Venture
2/15/2012
Lonza confirms to be in discussions and negotiations with the South African Government regarding the establishment of a local joint venture called Ketlaphela for the establishment of a local manufacturing facility for Anti-Retroviral Medicines.
